Balveen Kaur
Affiliations: | Neuroscience | Ohio State University, Columbus, Columbus, OH |
Area:
Neuroscience BiologyGoogle:
"Balveen Kaur"Mean distance: 53433
Parents
Sign in to add mentorPaul W. Doetsch | grad student | (Chemistry Tree) | |
Erwin G. Van Meir | post-doc | 1999-2005 |
Children
Sign in to add traineeChristopher Alvarez-Breckenridge | grad student | Ohio State | |
Chelsea Bolyard | grad student | Ohio State | |
Jayson Hardcastle | grad student | Ohio State | |
Hans Meisen | grad student | Ohio State | |
Jeffrey Wojton | grad student | Ohio State | |
Jeffrey Wojton | grad student | Ohio State | |
Amy M. Haseley | grad student | 2012 | Ohio State |
Ji Young Yoo | post-doc | Ohio State |
Collaborators
Sign in to add collaboratorMichael A. Caligiuri | collaborator | City of Hope (Cell Biology Tree) | |
E. Antonio Chiocca | collaborator | ||
Avner Friedman | collaborator | Ohio State | |
Joseph C. Glorioso | collaborator | ||
Maninder Khosla | collaborator | ||
Tae Jin Lee | collaborator | UTHSC-Houston | |
Vinay Puduvalli | collaborator | ||
Jianhua yu | collaborator | City of Hope |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Li X, Yan X, Wang Y, et al. (2023) The Notch signaling pathway: a potential target for cancer immunotherapy. Journal of Hematology & Oncology. 16: 45 |
Sahu U, Mullarkey MP, Pei G, et al. (2023) oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy. Molecular Therapy Oncolytics. 29: 30-41 |
Hong B, Sahu U, Mullarkey MP, et al. (2023) PKR induces TGF-β and limits oncolytic immune therapy. Journal For Immunotherapy of Cancer. 11 |
Swanner J, Shim JS, Rivera-Caraballo KA, et al. (2023) esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation. Molecular Therapy Oncolytics. 28: 171-181 |
Saini U, Smith BQ, Dorayappan KDP, et al. (2023) Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus. Journal of Ovarian Research. 16: 38 |
Saini U, Smith BQ, Dorayappan KDP, et al. (2022) Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus. Journal of Ovarian Research. 15: 130 |
Tian L, Xu B, Chen Y, et al. (2022) Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity. Nature Cancer |
Banasavadi-Siddegowda YK, Namagiri S, Otani Y, et al. (2022) Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib. Neuro-Oncology Advances. 4: vdac095 |
Rivera-Caraballo KA, Nair M, Lee TJ, et al. (2022) The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics. Molecular Therapy Oncolytics. 26: 63-75 |
Anami Y, Otani Y, Xiong W, et al. (2022) Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors. Cell Reports. 39: 110839 |